SCHEMBL1361518

SCHEMBL1361518

N#CNc1c(Cl)cccc1Cl

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
GFER P55789 1/20 0.39
PTK2B Q14289 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP2A6 P11509 1/20 0.38
PSMB8 P28062 3/20 0.37
TSHR P16473 1/20 0.36
ADRA2A P08913 2/20 0.35
ADRA2C P18825 2/20 0.35
ADRA1D P25100 2/20 0.35
ADRA1A P35348 2/20 0.35
ADRA1B P35368 2/20 0.35
DYRK1A Q13627 1/20 0.34
TAS1R3 Q7RTX0 1/20 0.34
TAS1R1 Q7RTX1 1/20 0.34
TAS1R2 Q8TE23 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094076 0.75 CYP1A2 (0.38) LMNAGAAMAPTGFERPTK2B
SCHEMBL3168133 0.73 ALDH1A1 (0.43) LMNAMAPTSMN1; SMN2CYP1A2TSHR
SCHEMBL10512435 0.70 KMT2A (0.35) MEN1KMT2AKDM4EALDH1A1HPGD
SCHEMBL11187663 0.70 CYP1A2 (0.39) LMNAGAAMAPTGFERPTK2B
SCHEMBL1686581 0.69 ADRA2A (0.52) LMNAGAACYP1A2CYP2A6TSHR
SCHEMBL16119585 0.67 SRC (0.43) LMNAGAAMAPTGFERPTK2B
SCHEMBL1361442 0.67 TAAR1 (0.41) GAAMAPTSMN1; SMN2TDP1CYP1A2
SCHEMBL2295342 0.65 KMT2A (0.53) LMNAGAAMAPTSMN1; SMN2TDP1
SCHEMBL9511244 0.65 CYP1A2 (0.43) LMNAGAATDP1CYP1A2CYP2A6
SCHEMBL22489476 0.65 CYP1A2 (0.43) LMNAGAATDP1CYP1A2CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0008150-B1 2,6-DICHLOROPHENYL-SUBSTITUTED AMINO-IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARING SUCH DERIVATIVES AND PHARMACEUTICAL PREPARATIONS COMPRISING SAID DERIVATIVES Farmos-Yhtyma Oy (FI) 1982-04-28 EP claimed
EP-0008150-A2 2,6-Dichlorophenyl-substituted amino-imidazole derivatives, processes of preparing such derivatives and pharmaceutical preparations comprising said derivatives Farmos-Yhtyma Oy (FI) 1980-02-20 EP claimed
US-9765020-B2 Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis CELLIX BIO PRIVATE LIMITED (IN) 2017-09-19 US disclosed
US-9765020-B2 Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis CELLIX BIO PRIVATE LIMITED (IN) 2017-09-19 US disclosed
US-20150307446-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS CELLIX BIO PRIVATE LIMITED (IN) 2015-10-29 US disclosed
US-20150307446-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS CELLIX BIO PRIVATE LIMITED (IN) 2015-10-29 US disclosed
WO-2013175377-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS KANDULA MAHESH (IN) 2013-11-28 WO disclosed
US-8067614-B2 N-substituted (benzoimidazol-2-yl)phenylamines, processes for their preparation, their use as a medicament or diagnostic aid, and a medicament comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2011-11-29 US disclosed
US-20100168196-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2010-07-01 US disclosed
EP-1857445-B1 Substituted 2 amino imidazoles, method for their manufacture and their use as a drug or diagnostic and drug containing them SANOFI AVENTIS DEUTSCHLAND (DE) 2009-07-15 EP disclosed
US-20080275098-A1 Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-11-06 US disclosed
WO-2004069811-A1 N-SUBSTITUTED (BENZOIMIDAZOLE-2-YL) PHENYL AMINES, METHOD FOR THEIR PRODUCTION, THEIR USE AS A MEDICAMENT OR DIAGNOSTIC AGENT AND MEDICAMENT CONTAINING SAID SUBSTANCES AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-19 WO disclosed
WO-2004069806-A2 SUBSTITUTED 2-AMINOIMIDAZOLES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS A MEDICAMENT OR AS A DIAGNOSTIC REAGENT, AND MEDICAMENT CONTAINING THESE COMPOUNDS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2004-08-19 WO disclosed
EP-0008150-B1 2,6-DICHLOROPHENYL-SUBSTITUTED AMINO-IMIDAZOLE DERIVATIVES, PROCESSES OF PREPARING SUCH DERIVATIVES AND PHARMACEUTICAL PREPARATIONS COMPRISING SAID DERIVATIVES Farmos-Yhtyma Oy (FI) 1982-04-28 EP disclosed
US-4290971-A HYPOTENSIVE AGENTS DSO "PHARMACHIM" (BG) 1981-09-22 US disclosed
US-4275072-A 2,6-Dichlorophenyl-substituted amino-imidazole derivatives and use as hypertensive agents FARMOS GROUP, LTD. (FI) 1981-06-23 US disclosed
EP-0008150-A2 2,6-Dichlorophenyl-substituted amino-imidazole derivatives, processes of preparing such derivatives and pharmaceutical preparations comprising said derivatives Farmos-Yhtyma Oy (FI) 1980-02-20 EP disclosed
US-4146647-A PHENYLAMIDOXIMES, HYPOTENSIVE AGENTS LABORATOIRE L. LAFON (FR) 1979-03-27 US disclosed
US-4101675-A ANTIHYPERTENSIVES AKZONA INCORPORATED (US) 1978-07-18 US disclosed
US-3972932-A Novel 2,6-disubstituted phenyl-aminoguanidine compounds AKZONA INCORPORATED (US) 1976-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275098-A1 Inhibit sodium proton exchangers; central nervous system, respiratory system, cardiovascular, urogenital, pyschological, biliary function and kidney disorders; sleep apnea, strokes; ketalization, acetalization, cyclization; similar to clonidine; hypotensive, antidiabetic, and antiischemic agents ATP6V1B1, SLC10A1, GLS LMNA 2655/4885GAA 576/4885MAPT 4163/4885
US-20100168196-A1 N-Substituted (Benzoimidazol-2-yl)phenylamines, Processes for Their Preparation, Their Use as a Medicament or Diagnostic Aid, and a Medicament Comprising Them SLC10A1, SLC9A3, ABCB11 LMNA 751/4885GAA 905/4885MAPT 4360/4885
US-20150307446-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF MUCOSITIS MUC1, SI, ALPI LMNA 3373/4885GAA 2308/4885MAPT 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.